Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F26%3AW0000069" target="_blank" >RIV/00064211:_____/26:W0000069 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064190:_____/26:10001442

Výsledek na webu

<a href="https://oadoi.org/10.1002/2056-4538.70087" target="_blank" >https://oadoi.org/10.1002/2056-4538.70087</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/2056-4538.70087" target="_blank" >10.1002/2056-4538.70087</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases

Popis výsledku v původním jazyce

Folate receptor alpha (FR alpha) is a promising therapeutic target due to its high expression in several tumor types and its rare expression in healthy tissue. Recently, the antibody-drug conjugate mirvetuximab soravtansine has been approved for treatment of advanced platinum-resistant high-grade serous carcinoma (HGSC). Immunohistochemical expression of FR alpha has been extensively studied in HGSC, but most studies conducted before the clinical studies targeting FR alpha used variable antibodies and scoring criteria, which makes comparison of older literature data with recent studies difficult. Moreover, the data regarding its expression in other types of ovarian and other female genital tract tumors are limited or absent. In our study, we focused on immunohistochemical expression in 923 tubo-ovarian and endometrial tumors (assessed on tissue microarrays), using standardized scoring criteria and the VENTANA FOLR1 CDx assay. The results of our study showed the highest FR alpha expression in serous carcinomas, specifically HGSC (45% positive cases), followed by low-grade serous carcinoma (25%), endometrial serous carcinoma (11%), and serous borderline tumor (10%). Endometrioid and clear cell ovarian carcinomas showed rare positivity (2% and 1%, respectively). All other tumors examined were negative, including mucinous ovarian tumors, sex cord-stromal tumors, endometrial endometrioid carcinomas, undifferentiated and dedifferentiated carcinomas, and endometrial clear cell carcinomas. In conclusion, these results confirm that FR alpha expression in HGSC and LGSC reaches similar values compared to published data, and is present in a minority of endometrial serous carcinomas. In other ovarian and endometrial tumors examined, FR alpha expression is absent or rare.

Název v anglickém jazyce

Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases

Popis výsledku anglicky

Folate receptor alpha (FR alpha) is a promising therapeutic target due to its high expression in several tumor types and its rare expression in healthy tissue. Recently, the antibody-drug conjugate mirvetuximab soravtansine has been approved for treatment of advanced platinum-resistant high-grade serous carcinoma (HGSC). Immunohistochemical expression of FR alpha has been extensively studied in HGSC, but most studies conducted before the clinical studies targeting FR alpha used variable antibodies and scoring criteria, which makes comparison of older literature data with recent studies difficult. Moreover, the data regarding its expression in other types of ovarian and other female genital tract tumors are limited or absent. In our study, we focused on immunohistochemical expression in 923 tubo-ovarian and endometrial tumors (assessed on tissue microarrays), using standardized scoring criteria and the VENTANA FOLR1 CDx assay. The results of our study showed the highest FR alpha expression in serous carcinomas, specifically HGSC (45% positive cases), followed by low-grade serous carcinoma (25%), endometrial serous carcinoma (11%), and serous borderline tumor (10%). Endometrioid and clear cell ovarian carcinomas showed rare positivity (2% and 1%, respectively). All other tumors examined were negative, including mucinous ovarian tumors, sex cord-stromal tumors, endometrial endometrioid carcinomas, undifferentiated and dedifferentiated carcinomas, and endometrial clear cell carcinomas. In conclusion, these results confirm that FR alpha expression in HGSC and LGSC reaches similar values compared to published data, and is present in a minority of endometrial serous carcinomas. In other ovarian and endometrial tumors examined, FR alpha expression is absent or rare.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2026

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JOURNAL OF PATHOLOGY CLINICAL RESEARCH

ISSN

—

e-ISSN

2056-4538

Svazek periodika

12

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

-

Kód UT WoS článku

001720434400001

EID výsledku v databázi Scopus

—